Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalized with COVID-19, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.
Why nearly half of Americans with Parkinson’s don’t see a neurologist
It took Richard Huckabee nine years to get a Parkinson’s diagnosis. A district manager for a convenience store chain, he first noticed symptoms in 2004
July 10, 2023